Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Abstract

PURPOSE:

To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies.

PATIENTS AND METHODS:

Patients received PS-341 twice weekly for 4 weeks at either 0.40, 1.04, 1.20, or 1.38 mg/m(2), followed by a 2-week rest. The PD of PS-341 was evaluated by measurement of whole blood 20S proteasome activity.

RESULTS:

Twenty-seven patients received 293 doses of PS-341, including 24 complete cycles. DLTs at doses above the 1.04-mg/m(2) MTD attributed to PS-341 included thrombocytopenia, hyponatremia, hypokalemia, fatigue, and malaise. In three of 10 patients receiving additional therapy, serious reversible adverse events appeared during cycle 2, including one episode of postural hypotension, one systemic hypersensitivity reaction, and grade 4 transaminitis in a patient with hepatitis C and a substantial acetaminophen ingestion. PD studies revealed PS-341 induced 20S proteasome inhibition in a time-dependent manner, and this inhibition was also related to both the dose in milligrams per meter squared, and the absolute dose of PS-341. Among nine fully assessable patients with heavily pretreated plasma cell dyscrasias completing one cycle of therapy, there was one complete response and a reduction in paraprotein levels and/or marrow plasmacytosis in eight others. In addition, one patient with mantle cell lymphoma and another with follicular lymphoma had shrinkage of nodal disease.

CONCLUSION:

PS-341 was well tolerated at 1.04 mg/m(2) on this dose-intensive schedule, although patients need to be monitored for electrolyte abnormalities and late toxicities. Additional studies are indicated to determine whether incorporation of dose/body surface area yields a superior PD model to dosing without normalization. PS-341 showed activity against refractory multiple myeloma and possibly non-Hodgkin's lymphoma in this study, and merits further investigation in these populations.

• Authors: Robert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, Thomas C Shea, Albert S Baldwin, Stephanie Stahl, Julian Adams, Dixie-Lee Esseltine, Peter J Elliott, Christine S Pien, Roberto Guerciolini, Jessica K Anderson, Natalie D Depcik-Smith, Rita Bhagat, Mary Jo Lehman, Steven C Novick, Owen A O'Connor, Steven L Soignet
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 20 Issue 22 Pg. 4420-7 (Nov 15 2002) ISSN: 0732-183X [Print] United States
• PMID: 12431963 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Boronic Acids
• Enzyme Inhibitors
• Multienzyme Complexes
• Pyrazines
• Bortezomib
• Cysteine Endopeptidases
• Proteasome Endopeptidase Complex

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects, chemistry, pharmacology)
• Boronic Acids (administration & dosage, adverse effects, chemistry, pharmacology)
• Bortezomib
• Cysteine Endopeptidases
• Drug Administration Schedule
• Enzyme Inhibitors (administration & dosage, adverse effects, chemistry, pharmacology)
• Female
• Hematologic Neoplasms (drug therapy, pathology)
• Humans
• Male
• Middle Aged
• Multienzyme Complexes (antagonists & inhibitors)
• Proteasome Endopeptidase Complex
• Pyrazines (administration & dosage, adverse effects, chemistry, pharmacology)
• Treatment Outcome
• United States